"Receptors, Glucagon" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind glucagon with high affinity and trigger intracellular changes which influence the behavior of cells. Activation of glucagon receptors causes a variety of effects; the best understood is the initiation of a complex enzymatic cascade in the liver which ultimately increases the availability of glucose to body organs.
| Descriptor ID |
D018027
|
| MeSH Number(s) |
D12.776.543.750.695.330 D12.776.543.750.750.580.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Glucagon".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Glucagon".
This graph shows the total number of publications written about "Receptors, Glucagon" by people in this website by year, and whether "Receptors, Glucagon" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Glucagon" by people in Profiles.
-
Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 Oct; 64(4):731-7.
-
Chagra SL, Zavala JK, Hall MV, Gosselink KL. Acute and repeated restraint differentially activate orexigenic pathways in the rat hypothalamus. Regul Pept. 2011 Feb 25; 167(1):70-8.
-
Bulut K, Pennartz C, Felderbauer P, Meier JJ, Banasch M, Bulut D, Schmitz F, Schmidt WE, Hoffmann P. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur J Pharmacol. 2008 Jan 14; 578(2-3):279-85.